Citryll
PrivateLast Round
Series B
Dec 9, 2024
Total Funding Raised
$110.96M
Company Overview
Citryll operates in Healthcare & Life Sciences and is based in Oss. Its latest recorded funding round was a Series B round in December 2024.
Citryll is a biotechnology company that develops pharmaceutical drugs designed to treat autoimmune and other human diseases by targeting Neutrophil Extracellular Traps (NETs).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Citryll Comparables
Compare Citryll with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neutrolis Inc | 85% | |
| Bristol Myers Squibb | 72% | |
| AstraZeneca | 69% |
For institutional investors. Book with your work email.
Citryll Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 9, 2024 | ||||
| Grant | Oct 3, 2024 | ||||
| Series A | Jul 2, 2020 | ||||
| Grant | Jul 2, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Citryll Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B |
| Brabantse Ontwikkelings Maatschappij | Series B |
| BOM Brabant Ventures | Series B, Series A |
| Pureos Bioventures | Series B |
| BioGeneration Ventures | Series B, Series A |
| Bgvcat | Series A, Series B |
| Johnson & Johnson Innovation - JJDC, Inc. | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
Developing the first ET-targeting therapy for immune-mediated inflammatory diseases.
- Jun 30, 2025
CIT-013 is a first-in-class antibody for immune-mediated inflammatory diseases.
For institutional investors. Book with your work email.
Citryll Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Citryll's valuation, stock price, and market status.
Is Citryll a public or private company?
Citryll is a private company.
What is the current stock price of Citryll?
Citryll is a private company, so its shares have no public market price. Caplight tracks Citryll's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Citryll worth (valuation)?
Valuation information for Citryll is not publicly available.
Can I buy Citryll stock?
Citryll shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Citryll's last funding round?
Citryll's most recent funding round was Series B on December 9, 2024.
Who are the main investors in Citryll?
Key investors in Citryll include Forbion, BioGeneration Ventures, Bgvcat, Johnson & Johnson Innovation - JJDC, Inc., Seventure Partners.
Will Citryll IPO soon?
No public IPO plans have been announced for Citryll.
How can I track Citryll secondary market activity?
Caplight tracks bids, offers, and trades in Citryll's shares on secondary markets.